AIP
TNGX icon

Arrowpoint Investment Partners’s Tango Therapeutics TNGX Stock Holding History

Arrowpoint Investment Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
7,658
-12,805
-63% -$317K 0.05% 100
2026
Q1 		$428K Buy
+20,463
New +$285K 0.38% 46

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Arrowpoint Investment Partners's TNGX Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Tango Therapeutics (TNGX) stake by 63% in Q2 2026, selling an estimated $317K and leaving 7,658 shares worth $239K. The position accounts for 0.05% of the portfolio, ranked #100.

Arrowpoint Investment Partners first reported a position in TNGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $428K in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Arrowpoint Investment Partners held 7,658 shares of Tango Therapeutics worth $239K as of Q2 2026.
  • Arrowpoint Investment Partners sold 12,805 Tango Therapeutics shares in Q2 2026, an estimated $317K.
  • Tango Therapeutics made up 0.05% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #100 holding.
  • Arrowpoint Investment Partners first reported a position in Tango Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Tango Therapeutics position peaked at $428K in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.